BioMarin Pharmaceutical (BMRN) : During the past 4 weeks, traders have been relatively bearish on BioMarin Pharmaceutical (BMRN), hence the stock is down -2.83% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.17% relative to the S&P 500. The 4-week change in the price of the stock is -3.35% and the stock has fallen -5.01% in the past 1 week.
The stock has recorded a 20-day Moving Average of 3.72% and the 50-Day Moving Average is 3.44%.The 200 Day SMA reached 5.22%
BioMarin Pharmaceutical (NASDAQ:BMRN): The stock opened in the green at $93.08 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $93.325 and a low of $91.2 for the day. The stock did not find buyers even at the lows and closed at $92.52 recording a loss of -0.28%. 1,476,016 shares exchanged hands during the trading day. The stock had closed at $92.52 in the previous days trading.
BioMarin Pharmaceutical (BMRN) stock is expected to deviate a maximum of $12.36 from the average target price of $118.36 for the short term period. 14 Street Experts have initiated coverage on the stock with the most promising target being $150 and the most muted being $99.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).